NEWS
Latest from Ounce Sachs
Latest from Ounce Sachs
Latest from Ounce Sachs
Corporate developments, scientific progress and selected updates from across Ounce Sachs and its Houses.
Corporate developments, scientific progress and selected updates from across Ounce Sachs and its Houses.
ALL NEWS CORPORATE SCIENCE & INNOVATION HOUSES CAPITAL MARKETS
ALL NEWS CORPORATE SCIENCE & INNOVATION HOUSES CAPITAL MARKETS
REVERSE CHRONOLOGICAL ORDER
REVERSE CHRONOLOGICAL ORDER

CAPITAL MARKETS
Following a decade of development across formulation science, intellectual property and specialist Houses, Ounce Sachs is entering its next phase with a private-capital strategy focused on commercialisation, institutional development and long-term growth.
Following a decade of development across formulation science, intellectual property and specialist Houses, Ounce Sachs is entering its next phase with a private-capital strategy focused on commercialisation, institutional development and long-term growth.

CORPORATE
An independent valuation completed on 2 August 2026 assessed the Ounce Sachs portfolio at approximately US$37.66 million, providing an independent reference point for the Group’s intellectual-property and brand portfolio as it enters its next stage of development.
An independent valuation completed on 2 August 2026 assessed the Ounce Sachs portfolio at approximately US$37.66 million, providing an independent reference point for the Group’s intellectual-property and brand portfolio as it enters its next stage of development.
OUNCE SACHS
OUNCE SACHS
A global healthcare, personal care and consumer brand group.
A global healthcare, personal care and consumer brand group.
© 2026 OUNCE SACHS
© 2026 OUNCE SACHS